ClinicalTrials.gg
CompletedNCT03317301Updated Aug 28, 2018

Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus

A Phase 3 interventional study of HL151 and Talion Tab in Pruritus, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-08-28.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Pruritus with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Pruritus · Korea, Republic of.

Enrollment
12th of 20
189 · median 197
Started
2017
the only one that year
Phase 3
10 of 20
2 open now
Registered
10th of 20
by date
Lead sponsor
1 of 20
Hanlim Pharm. Co., Ltd.

Among the 20 studies in Pruritus with a site in Korea, Republic of, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 10 in phase 3, and was the 10th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 20 studies in Pruritus with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Pruritus with a site in Korea, Republic of, or all of them as a file.
02

Study summary

a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HL151 versus Talion Tab. in Pruritus cutaneus.

  • Endpoint: VAS Score Change, Investigator's assessment of overall treatment
03

Conditions studied

  • Pruritus

Browse trials for

Keywords

  • Pruritus cutaneus
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Both gender, 19 years ≤ age
  2. Patients with pruritus due to the following diseases

    ① acute eczema, chronic eczema, monetary eczema, sebaceous deficiency eczema

    ② contact dermatitis, atopic dermatitis, seborrheic dermatitis, neurodermatitis

    ③ Acute prurigo (Strofus, Urticaria, lichen urticatus), subacute prurigo, chronic prurigo (nodular prurigo)

    ④ systemic skin pruritus, focal skin pruritus

  3. In visit 2, during the run-in period previous week the VAS score of day and night time were 2 or more average points per day (maximum 4 points)
  4. Those who can ability to record subject diary
  5. Written consent voluntarily to participate in this clinical trial after understanding and detailed explanation about this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Patients with pruritus due other medical causes (liver disease, heart failure, etc.)
  2. Among patients with skin disease, malignant tumors and patients with chronic urticaria skin disease
  3. Patients with systemic infection symptoms at the time of clinical trials
  4. Asthmatic patients requiring treatment
  5. Patients with Spastic diseases such as epilepsy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    Experimental

    Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)

    Drug: HL151

  • Active comparator
    Active comparator

    Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)

    Drug: Talion Tab

Interventions

  • DrugHL151

    2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)

  • DrugTalion Tab

    2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)

06

What researchers measure

Primary outcomes

  1. Changes in VAS(Visual Analogue Scale) score at 2nd week after clinical drug administration compared to baseline

    VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)

    Time frame: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)

Secondary outcomes

  1. Changes in VAS(Visual Analogue Scale) score at 1st week after clinical drug administration

    VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 2 (0 week), Visit 3 (1 week)

    Time frame: Visit 2 (0 week), Visit 3 (1 week)

  2. Changes in VAS(Visual Analogue Scale) score at 1st and 2nd week(Day) after clinical drug administration compared to baseline

    VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks

    Time frame: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks

  3. Changes in VAS(Visual Analogue Scale) score at 1st and 2nd week after clinical drug administration compared to baseline

    VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)

    Time frame: Visit 2 (0 week), Visit 3 (1 week), Visit 4 (2 weeks)

  4. Investigator's assessment of overall treatment(Cochran-Mantel-Haenszel method)

    VAS score: 0 Point \~ 10 Point (asymptomatic \~ Maximum pruritus) * Evaluation period: Visit 4 (2 weeks)

    Time frame: Visit 4 (2 weeks)

07

Study locations

1 site
  • Hanyang Univ. Guri Hospital
    Guri-si, Kyeonggi-do 471-701, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Nov 2017, 5 months.

Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2017
First posted
Oct 23, 2017
StartActual
May 17, 2017
Primary completionActual
Nov 13, 2017
CompletionActual
Jan 30, 2018
Last update
Aug 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03317301
Responsible party
Sponsor
First posted
Oct 23, 2017
Start date
May 17, 2017
Primary completion
Nov 13, 2017
Completion
Jan 30, 2018
Last update
Aug 28, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HL151

Start the discussion